A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-23

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with Non-Muscle-Invasive Bladder Cancer (NMIBC)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461

Non Muscle Invasive Bladder Cancer

COMPLETED PHASE2

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

NCT03519256

Urinary Bladder Neoplasms

TERMINATED PHASE2

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

NCT02138734

Non-muscle Invasive Bladder Cancer

RECRUITING PHASE1/PHASE2

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614

Nonmuscle-invasive Bladder Cancer

RECRUITING PHASE2

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

NCT01697306

Bladder Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study starts with a dose escalation part followed by a dose expansion part. The primary objective of the dose escalation part is to evaluate the safety and tolerability of SIM0237 alone or in combination with BCG, and determine the recommended dose(s) (RD). The primary objective of the dose expansion part is to evaluate the preliminary efficacy of SIM0237 alone or in combination with BCG.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose escalation-mono

BCG-unresponsive high-risk NMIBC, receiving SIM0237 monotherapy intravesically.

Group Type EXPERIMENTAL

SIM0237

Intervention Type DRUG

Several dose levels of SIM0237 will be administered as a single agent for evaluation

Dose escalation-combo

BCG-unresponsive high-risk NMIBC, receiving SIM0237 and BCG intravesically.

Group Type EXPERIMENTAL

SIM0237 and BCG

Intervention Type DRUG

Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Dose expansion-Cohort 1

BCG-unresponsive CIS, receiving SIM0237 monotherapy intravesically.

Group Type EXPERIMENTAL

SIM0237

Intervention Type DRUG

RD level of SIM0237 will be administered as a single agent for evaluation

Dose expansion-Cohort 3

BCG-unresponsive CIS, receiving SIM0237 and BCG intravesically.

Group Type EXPERIMENTAL

SIM0237 and BCG

Intervention Type DRUG

RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Dose expansion-Cohort 4

BCG-unresponsive high-risk Ta or T1, receiving SIM0237 and BCG intravesically.

Group Type EXPERIMENTAL

SIM0237 and BCG

Intervention Type DRUG

RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Dose expansion-Cohort 2

BCG-unresponsive high-risk Ta or T1, receiving SIM0237 monotherapy intravesically.

Group Type EXPERIMENTAL

SIM0237

Intervention Type DRUG

RD level of SIM0237 will be administered as a single agent for evaluation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SIM0237

Several dose levels of SIM0237 will be administered as a single agent for evaluation

Intervention Type DRUG

SIM0237 and BCG

Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Intervention Type DRUG

SIM0237

RD level of SIM0237 will be administered as a single agent for evaluation

Intervention Type DRUG

SIM0237 and BCG

RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent.
* ≥ 18 years of age, male or female.
* • Histologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1 disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1 disease. Histologic confirmation of urothelial carcinoma (mixed histology tumors allowed if urothelial histology is predominant histology).
* Dose escalation phase: BCG-unresponsive high-risk NMIBC.
* Dose expansion phase: a) Cohorts 1 and 3: BCG-unresponsive CIS (with or without Ta or T1 disease); b) Cohort 2 and 4: BCG-unresponsive high-risk Ta or T1 disease.
* Absence of resectable disease after transurethral resection (TURBT) procedures \[residual carcinoma in situ (CIS) acceptable\]. patients with T1 tumors must undergo repeat resection and pathological test if initial pathological test sample did not include muscularis propria, to ensure the inclusive of muscularis propria and the absence of invasive tumor.
* Not suitable for or unwilling to undergo radical cystectomy.
* ECOG performance status of 0, 1or 2.
* Life expectancy ≥ 2 years.
* Adequate hematologic and organ function.
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. WOCBP and male subjects agree to use adequate contraception.
* Tumor tissue (archival or fresh) for biomarker analysis.

Exclusion Criteria

* • Subjects received TURBT or other surgical treatment for bladder lesions or pelvic radiotherapy or interventional therapy within 2 weeks prior to the first dose.
* Previous treatment with: a) IL-15 or IL-2; b) immune checkpoint inhibitors (such as anti-PD-1 or PD-L1 antibodies), ADCs, chemotherapies, oncolytic viruses, BCG or other anti-tumor treatments, unless there is clear evidence of disease persistence/recurrence/progression after the above treatments and beyond 4 weeks prior to the first dose; c) Chinese herbal medicine treatment beyond 2 weeks prior to the first dose is allowed; d) A single immediate instillation of chemotherapy within 4 weeks prior to the first dose is allowed; e) intravesical instillation of mucosal protective agents (e.g., sodium hyaluronate) are allowed.
* Subject is participating in an investigational drug or investigational device study.
* Subjects have not recovered from AEs caused by previous anti-tumor treatment.
* History/evidence of prior muscle-invasive, locally advanced, metastatic bladder cancer or upper urinary tract (kidney, renal pelvis, ureter) and prostatic urethral tumors; or evidence of Ta/T1/CIS urothelial transitional cell carcinoma outside the bladder (urethra, ureter, renal pelvis) during the screening period.
* Patients with other malignancies within 5 years before the first dose.
* Any active infection or urinary tract infection requiring systemic treatment by intravenous infusion within 2 weeks before the first dose.
* Subjects with clinically significant cardiovascular disease within 6 months before the first dose of study treatment.
* Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
* Active or chronic hepatitis B or hepatitis C infection.
* Known or suspected active autoimmune diseases.
* Concurrent use of any other anticancer therapy or chronic use of systemic corticosteroids at immunosuppressive doses (more than 10 mg/day prednisone or equivalent).
* History of pneumonitis or interstitial lung disease or severe obstructive pulmonary disease that requires oral or intravenous steroids to help recover.
* Known to be allergic or intolerant to study drugs, monoclonal antibodies, excipients; or allergic or intolerant to BCG (only for subjects receiving combined BCG therapy)
* Subjects discontinued prior BCG treatment due to AEs such as toxemia, systemic infection, or urinary incontinence (only for subjects receiving combined BCG therapy).
* History of allogeneic organ transplantation or graft-versus-host disease.
* Any live vaccines within 4 weeks before the first dose.
* Known mental illness or substance abuse that would interfere with trial complies.
* Subject is pregnant or lactating, or is expected to become pregnant or parent a child during the planned study period.
* Other conditions that investigators consider inappropriate for inclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University Third Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status RECRUITING